Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies

The importance of <i>Streptococcus pneumoniae</i> has been well established. These bacteria can colonize infants and adults without symptoms, but in some cases can spread, invade other tissues and cause disease with high morbidity and mortality. The development of pneumococcal conjugate...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Giuliana S. Oliveira, Maria Leonor S. Oliveira, Eliane N. Miyaji, Tasson C. Rodrigues
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	<i>Streptococcus pneumoniae</i> pneumococcus vaccine PCV PPV whole cell Medicine R
Acceso en línea:	https://doaj.org/article/b907d4338b664037ace60ac367dfb26a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b907d4338b664037ace60ac367dfb26a
record_format	dspace
spelling	oai:doaj.org-article:b907d4338b664037ace60ac367dfb26a2021-11-25T19:11:26ZPneumococcal Vaccines: Past Findings, Present Work, and Future Strategies10.3390/vaccines91113382076-393Xhttps://doaj.org/article/b907d4338b664037ace60ac367dfb26a2021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1338https://doaj.org/toc/2076-393XThe importance of <i>Streptococcus pneumoniae</i> has been well established. These bacteria can colonize infants and adults without symptoms, but in some cases can spread, invade other tissues and cause disease with high morbidity and mortality. The development of pneumococcal conjugate vaccines (PCV) caused an enormous impact in invasive pneumococcal disease and protected unvaccinated people by herd effect. However, serotype replacement is a well-known phenomenon that has occurred after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) and has also been reported for other PCVs. Therefore, it is possible that serotype replacement will continue to occur even with higher valence formulations, but the development of serotype-independent vaccines might overcome this problem. Alternative vaccines are under development in order to improve cost effectiveness, either using proteins or the pneumococcal whole cell. These approaches can be used as a stand-alone strategy or together with polysaccharide vaccines. Looking ahead, the next generation of pneumococcal vaccines can be impacted by the new technologies recently approved for human use, such as mRNA vaccines and viral vectors. In this paper, we will review the advantages and disadvantages of the addition of new polysaccharides in the current PCVs, mainly for low- and middle-income countries, and we will also address future perspectives.Giuliana S. OliveiraMaria Leonor S. OliveiraEliane N. MiyajiTasson C. RodriguesMDPI AGarticle<i>Streptococcus pneumoniae</i>pneumococcusvaccinePCVPPVwhole cellMedicineRENVaccines, Vol 9, Iss 1338, p 1338 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	<i>Streptococcus pneumoniae</i> pneumococcus vaccine PCV PPV whole cell Medicine R
spellingShingle	<i>Streptococcus pneumoniae</i> pneumococcus vaccine PCV PPV whole cell Medicine R Giuliana S. Oliveira Maria Leonor S. Oliveira Eliane N. Miyaji Tasson C. Rodrigues Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies
description	The importance of <i>Streptococcus pneumoniae</i> has been well established. These bacteria can colonize infants and adults without symptoms, but in some cases can spread, invade other tissues and cause disease with high morbidity and mortality. The development of pneumococcal conjugate vaccines (PCV) caused an enormous impact in invasive pneumococcal disease and protected unvaccinated people by herd effect. However, serotype replacement is a well-known phenomenon that has occurred after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) and has also been reported for other PCVs. Therefore, it is possible that serotype replacement will continue to occur even with higher valence formulations, but the development of serotype-independent vaccines might overcome this problem. Alternative vaccines are under development in order to improve cost effectiveness, either using proteins or the pneumococcal whole cell. These approaches can be used as a stand-alone strategy or together with polysaccharide vaccines. Looking ahead, the next generation of pneumococcal vaccines can be impacted by the new technologies recently approved for human use, such as mRNA vaccines and viral vectors. In this paper, we will review the advantages and disadvantages of the addition of new polysaccharides in the current PCVs, mainly for low- and middle-income countries, and we will also address future perspectives.
format	article
author	Giuliana S. Oliveira Maria Leonor S. Oliveira Eliane N. Miyaji Tasson C. Rodrigues
author_facet	Giuliana S. Oliveira Maria Leonor S. Oliveira Eliane N. Miyaji Tasson C. Rodrigues
author_sort	Giuliana S. Oliveira
title	Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies
title_short	Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies
title_full	Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies
title_fullStr	Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies
title_full_unstemmed	Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies
title_sort	pneumococcal vaccines: past findings, present work, and future strategies
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/b907d4338b664037ace60ac367dfb26a
work_keys_str_mv	AT giulianasoliveira pneumococcalvaccinespastfindingspresentworkandfuturestrategies AT marialeonorsoliveira pneumococcalvaccinespastfindingspresentworkandfuturestrategies AT elianenmiyaji pneumococcalvaccinespastfindingspresentworkandfuturestrategies AT tassoncrodrigues pneumococcalvaccinespastfindingspresentworkandfuturestrategies
_version_	1718410178049605632

Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies

Ejemplares similares